Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Net Income
(77,211)
(117,042)
(630,210)
(171,799)
Operating Activities, Cash Flows Provided By or Used In
Depreciation
95,671
87,861
96,912
47,187
Changes In Accounts Receivables
(54,274)
(25,256)
(51,483)
(16,367)
Changes In Assets and Liabilities
(49,420)
(93,963)
(160,276)
46,332
Changes In Inventories
(23,747)
(96,890)
(64,512)
(50,989)
Changes In Other Operating Activities
129,189
236,533
581,732
(76,053)
Total Cash Flow From Operating Activities
20,208
(8,757)
(227,837)
(221,689)
Investing Activities, Cash Flows Provided By or Used In
Capital Expenditures
(144,620)
(199,219)
(148,380)
(227,653)
Investments
358,981
(229,487)
(332,180)
(451,797)
Other Cash flows from Investing Activities
49,990
123,247
(3,487)
(500,148)
Total Cash Flows From Investing Activities
264,351
(305,459)
(484,047)
(1,179,598)
Financing Activities, Cash Flows Provided By or Used In
Dividends Paid
--
--
--
--
Sale/Purchase of Stock
0
0
712,938
888,257
Net Borrowings
(374,953)
481,687
0
(163)
Other Cash Flows from Financing Activities
(13,054)
25,458
14,170
39,819
Total Cash Flows From Financing Activities
(388,007)
507,145
727,108
927,913
Effect Of Exchange Rate Changes
(598)
(3,231)
(3,934)
(5,072)
Change In Cash and Cash Equivalents
(103,448)
192,929
15,224
(473,374)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information